Table 2.
Maintenance remitter dose de‐escalation subpopulation | ||
---|---|---|
In remission at month 12 of OCTAVE Open (N = 47) | Not in remission at month 12 of OCTAVE Open (N = 19) | |
Age (y), mean (SD) | 45.9 (14.6) | 45.0 (16.6) |
Male, n (%) | 21 (44.7) | 11 (57.9) |
Mean body mass index, kg/m2 (SD) | 25.1 (4.1) | 27.2 (4.8) |
Total Mayo score at baseline of OCTAVE Open, mean (SD) | 1.1 (0.8) | 1.1 (0.7) |
Disease duration, n (%)a | ||
<6 y | 23 (48.9) | 9 (47.4) |
≥6 y | 24 (51.1) | 10 (52.6) |
Corticosteroid use at baseline of OCTAVE Open, n (%) | 0 (0.0) | 1 (5.3) |
Prior corticosteroid failure, n (%)a | 37 (78.7) | 15 (78.9) |
Prior immunosuppressant failure, n (%)a | 30 (63.8) | 13 (68.4) |
Prior tumour necrosis factor inhibitor failure, n (%)a | 20 (42.6) | 7 (36.8) |
Extent of disease, n/N1 (%)a | ||
Proctosigmoiditis | 9/46 (19.6) | 7/19 (36.8) |
Left‐sided colitis | 14/46 (30.4) | 8/19 (42.1) |
Extensive colitis/pancolitis | 23/46 (50.0) | 4/19 (21.1) |
Remission status at month 12 of OCTAVE Open was defined based on local read of endoscopy, using nonresponder imputation.
Abbreviations: N, number of evaluable patients; N1, number of patients with non‐missing data; n, number of patients; SD, standard deviation; y, years.
Data at baseline of induction studies.